Table 1.

Description of the NCO and 12 OCAC replication studies with IL18 rs1834481 genotype frequencies (G>C) by case status (listed alphabetically).

Study	Location	Case ascertainment	Cases (No.)			Control ascertainment*	Controls (No.)
			GG	GC	CC		GG	GC	CC
AUS (16)	Multiregional,Australia	Cancer registries,surgical treatment centres	475	359	85	P: Electoral roll	573	410	71
DOV (17)	Washington,USA	Cancer Surveillance System, SEER	411	272	55	P: RDD	422	271	46
GER (18)	Multiregional,Germany	Hospital admissions	143	89	13	P: Population registries	172	81	13
HAW (19)	Hawaii, USA	Hawaii Tumor Registry, SEER	56	30	2	P: Annual Hawaii Health Survey	91	57	8
HOP (20)	Ohio,Pennsylvania and New York,USA	Registries,Physician offices,pathology databases	174	124	20	P: RDD	367	233	36
MAL (21)	Multiregional,Denmark	Danish Cancer Registry, 16 Gynecologic departments	232	154	29	P: Danish Central Population Register	643	442	89
MAY (22)	Multiregional,USA	Mayo Clinic	221	142	13	C: Women seeking general exams at Mayo Clinic	245	186	22
NCO (15)	North Carolina, USA	NC Central Cancer Registry	450	334	64	P: RDD	470	285	43
SEA (6)	Cambridge,UK	East Anglia and West Midlands cancer registries	625	395	71	P: EPIC-Norfolk cohort	672	456	82
STA (23)	California,USA	Greater Bay Area Cancer Registry, SEER	201	102	16	P: RDD	244	141	28
UCI (24)	California,USA	Cancer Surveillance Program of Orange County,Tumor Registry	268	159	24	P: RDD	264	172	29
UKO (25)	Multiregional,UK	10 gynecologic Oncology National Health Service Centres	148	91	17	P: UK Collaborative Trial of Ovarian Cancer Screening & all women followed up for cancers by Office of National Statistics	302	231	43
USC (26)	California,USA	LA Cancer Surveillance Program	413	211	37	P: Neighborhood recruits	408	205	36
Totals	---	---	3,817	2,462	446	---	4,873	3,170	546

NCO, North Carolina Ovarian Cancer Study; OCAC, Ovarian Cancer Association Consortium; SEER, Surveillance Epidemiology and End Results; RDD, random digit dialing.

^*P=Population-based; C=Clinic-based.